UNSPSC 51432107: Guanoxyfen

This classification denotes an antihypertensive agent with the molecular formula C10H15N3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, 03HN50ZAF0 chemically known as cn-34,799-5a but generally known as guanoxyfen, which bears US NIH Compound Identifier 6332517. European Medicines Agency schedules Guanoxyfen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07990MIG.

The term GUANOXYFEN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 21 no. 12 1967, list 7. ). Most nations schedule guanoxyfen under HS 29252900 and SITC 51482. As of Q4 2014, GUANOXYFEN remains the US FDA Preferred Term for this commodity. Guanoxyfen bears US NLM identifiers UMLS ID C1881017 and NCI Concept Code C65835. SMILES: C1=CC=C(C=C1)OCCCN=C(N)N.[N+](=O)(O)O.

UNSPSC 51432107 Guanoxyfen is a Commodity code that captures state and local procurement of advanced life support and emergency medications supplied to public health and safety agencies. State and local governments buying under this code procure specific injectable pharmaceuticals—epinephrine, labetalol, adenosine, diltiazem, and related agents—for use by fire rescue services, emergency medical personnel, and public health programs. Issuing bodies include city purchasing departments acting on behalf of municipal fire and rescue operations, state health agencies coordinating multi-jurisdictional pharmacy benefit programs, and cooperative purchasing alliances serving multiple state and local members. Recent solicitations show Tampa Fire Rescue obtaining four medication line items through the City of Tampa's purchasing office, while the Texas Health and Human Services Commission and Minnesota's multistate cooperative purchasing alliance (MMCAP) are mapping broader pharmaceutical supply strategies that include guanoxyfen and related emergency medications within larger generic and specialty drug portfolios.

Geographic activity concentrates in Florida, Texas, and Minnesota based on recent postings. The City of Tampa issued an IFB (Bid No. 26-P-00188) in April 2026 with a response deadline of April 8, 2026, seeking 1,810 units of epinephrine 1:10,000 injections, 370 units of labetalol HCI 100mg vials, 330 units of adenosine 6mg vials, and 1,020 units of diltiazem 25mg vials for Tampa Fire Rescue, with an estimated contract value of $40,000, a one-year initial term, and renewal options; the solicitation included a 5 percent Small Local Business Enterprise bid discount. The Texas Health and Human Services Commission posted an RFI (HHS0017013) in April 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program covering multiple drug categories. Minnesota's MMCAP issued an RFP (S1070000015802) with a March 26, 2026 response deadline to establish statewide contracts for generic pharmaceuticals and OTC products across participating state and local facilities, with contract effectiveness set for July 1, 2026, and awards evaluated primarily on price competitiveness (75 percent weight) and compliance with cGMP and Drug Supply Chain Security Act requirements.